Skip to main content
Premium Trial:

Request an Annual Quote

Blueprint Genetics, BioMarin to Offer Genetic Testing for Skeletal Dysplasia in Europe, Middle East

NEW YORK ─ Blueprint Genetics said Tuesday it is collaborating with BioMarin to launch a free genetic testing program for people suspected of having inherited skeletal dysplasia.

The program, expected to launch this month for physicians in certain countries in Europe and the Middle East, aims to enable early detection and more precise diagnoses, leading to improved patient outcomes, Blueprint Genetics said.

Financial and other terms of the collaboration agreement were not disclosed.

According to Blueprint Genetics, patients should have at least one of the following clinical features to be eligible for the program — signs or symptoms suggestive of skeletal dysplasia; disproportionate growth; dysmorphic facial features; or abnormal gait with joint pain.

"An early molecular diagnosis can have considerable benefits for patients with skeletal dysplasia and is essential for optimizing care," Juha Koskenvuo, Blueprint Genetics executive director of Medical and Laboratory Director, said in a statement.

Eligible patients will have access to a Blueprint Genetics 419-gene panel that detects single nucleotide variants and provides an analysis of more than 180 noncoding variants associated with skeletal dysplasia. The panel also includes high-resolution detection of copy number variants, or CNVs.

Blueprint noted that a recent study published in the Orphanet Journal of Rare Diseases examining the genetic test results of 543 patients with suspected skeletal dysplasia found that CNVs accounted for more than 5 percent of diagnostic variants.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.